Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer's disease (Review)

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1533-1541

  Cai, Zhiyou ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Monoamine oxidase; Neurodegeneration; Tau; amyloid

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BRAIN ENZYME; LADOSTIGIL; MONOAMINE OXIDASE INHIBITOR; RASAGILINE; SELEGILINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN LEVEL; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; REVIEW; THROMBOCYTE;

ALZHEIMER DISEASE; ANIMALS; BLOOD PLATELETS; BRAIN; ENZYME ACTIVATION; HUMANS; MOLECULAR TARGETED THERAPY; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLES; NEUROPROTECTIVE AGENTS; PLAQUE, AMYLOID;

EID: 84899577518     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2040     Document Type: Review

References (149)

1. Said UZ, Saada HN, Abd-Alla MS, Elsayed ME and Amin AM: Hesperidin attenuates brain biochemical changes of irradiated rats. Int J Radiat Biol 88: 613-618, 2012.
2. Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL and Cole JO: Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis 184: 295-301, 1996.
3. Dunleavy DL: Mood and sleep changes with monoamine-oxidase inhibitors. Proc R Soc Med 66: 951, 1973.
4. Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E, Sandhu S, Nel W, Rais A, Sandhu R, Ngu N and Sharma S: Effect of diet on serotonergic neurotransmission in depression. Neurochem Int 62: 324-329, 2013.
5. Merikangas KR and Merikangas JR: Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression. Biol Psychiatry 38: 603-610, 1995.
6. Samson JA, Gurrera RJ, Nisenson L and Schildkraut JJ: Platelet monoamine oxidase activity and deficit syndrome schizophrenia. Psychiatry Res 56: 25-31, 1995.
7. Lawson DC, Turic D, Langley K, Pay HM, Govan CF, Norton N, Hamshere ML, Owen MJ, O'Donovan MC and Thapar A: Association analysis of monoamine oxidase A and attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 116B: 84-89, 2003. (Pubitemid 37063620)
8. Wargelius HL, Malmberg K, Larsson JO and Oreland L: Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity. Psychiatr Genet 22: 42-45, 2012.
9. Nedic G, Pivac N, Hercigonja DK, Jovancevic M, Curkovic KD and Muck-Seler D: Platelet monoamine oxidase activity in children with attention-deficit/ hyperactivity disorder. Psychiatry Res 175: 252-255, 2010.
10. Marziniak M, Mössner R, Benninghoff J, Syagailo YV, Lesch KP and Sommer C: Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine. J Neural Transm 111: 603-609, 2004. (Pubitemid 38530066)
11. Moreno ML, Villanúa MA and Esquifino AI: Serum prolactin and luteinizing hormone levels and the activities of hypothalamic monoamine oxidase A and B and phenylethanolamine-N-methyl transferase are changed during sexual maturation in male rats treated neonatally with melatonin. J Pineal Res 13: 167-1731, 1992.
12. Youdim MB, Fridkin M and Zheng H: Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transm 111: 1455-1471, 2004. (Pubitemid 39468399)
13. Huang L, Lu C, Sun Y, Mao F, Luo Z, Su T, Jiang H, Shan W and Li X: Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease. J Med Chem 55: 8483-8492, 2012.
14. Zheng H, Fridkin M and Youdim MB: From antioxidant chelators to site-activated multi-target chelators targeting hypoxia inducing factor, beta-amyloid, acetylcholinesterase and monoamine oxidase A/B. Mini Rev Med Chem 12: 364-370, 2012.
15. Gal S, Abassi ZA and Youdim MB: Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox Res 18: 143-150, 2010.
16. Youdim MB and Lavie L: Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. Life Sci 55: 2077-2082, 1994.
17. Youdim MB and Bakhle YS: Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147 (Suppl 1): S287-S296, 2006. (Pubitemid 43077287)
18. Naoi M, Maruyama W, Akao Y, Yi H and Yamaoka Y: Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm Suppl: 67-77, 2006. (Pubitemid 351412108)
19. Zheng H, Youdim MB and Fridkin M: Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem Biol 5: 603-610, 2010.
20. Cummings JL: Lewy body diseases with dementia: pathophysiology and treatment. Brain Cogn 28: 266-280, 1995.
21. Drozak J and Kozłowski M: Monoamine oxidase as a target for drug action. Postepy Hig Med Dosw (Online) 60: 498-515, 2006 (In Polish).
22. Siddiqui A, Mallajosyula JK, Rane A and Andersen JK: Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression. Neurobiol Dis 43: 527-532, 2011.
23. Bielecka AM, Paul-Samojedny M and Obuchowicz E: Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn Schmiedebergs Arch Pharmacol 382: 409-417, 2010.
24. Merad-Boudia M, Nicole A, Santiard-Baron D, Saillé C and Ceballos-Picot I: Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Biochem Pharmacol 56: 645-655, 1998. (Pubitemid 28458903)
25. Hüll M, Berger M and Heneka M: Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs 66: 2075-2093, 2006.
26. Rodríguez S, Ito T, He XJ, Uchida K and Nakayama H: Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B. Exp Toxicol Pathol 65: 127-133, 2013.
27. Konradi C, Riederer P, Jellinger K and Denney R: Cellular action of MAO inhibitors. J Neural Transm Suppl 25: 15-25, 1987.
28. Weinstock M, Luques L, Poltyrev T, Bejar C and Shoham S: Ladostigil prevents age-related glial activation and spatial memory deficits in rats. Neurobiol Aging 32: 1069-1078, 2011.
29. Spina MB and Cohen G: Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 86: 1398-1400, 1989. (Pubitemid 19061553)
30. Farooqui T and Farooqui AA: Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease. Parkinsons Dis 2011: 247467, 2011.
31. Loeffler DA, DeMaggio AJ, Juneau PL, Havaich MK and LeWitt PA: Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Clin Neuropharmacol 17: 370-379, 1994. (Pubitemid 24239388)
32. Tapia-González S, Giráldez-Pérez RM, Cuartero MI, Casarejos MJ, Mena MÁ, Wang XF and Sánchez-Capelo A: Dopamine and α-synuclein dysfunction in Smad3 null mice. Mol Neurodegener 6: 72, 2011.
33. Oberpichler-Schwenk H: Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment. Med Monatsschr Pharm 28: 224-227, 2005 (In German).
34. Chen JJ and Wilkinson JR: The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? J Clin Pharmacol 52: 620-628, 2012.
35. Oreland L and Gottfries CG: Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 10: 533-540, 1986. (Pubitemid 17172639)
36. Sherif F, Gottfries CG, Alafuzoff I and Oreland L: Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 4: 227-240, 1992.
37. Sparks DL, Woeltz VM and Markesbery WR: Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease. Arch Neurol 48: 718-721, 1991.
38. Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, Keller E, Horváth MC, Nag S, Hermecz I, Magyar K and Halldin C: Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int 58: 60-68, 2011.
39. Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, Oikonen V, Sipilä H, Ruokoniemi P, Virtanen K, Scheinin M and Rinne JO: Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther 85: 506-512, 2009.
40. Jossan SS, Gillberg PG, Karlsson I, Gottfries CG and Oreland L: Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study. J Neural Transm Suppl 32: 61-65, 1990.
41. Fischer P, Götz ME, Ellinger B, Streifler M, Riederer P and Danielczyk W: Platelet monoamine oxidase B activity and vitamin B12 in dementia. Biol Psychiatry 35: 772-774, 1994.
42. Muck-Seler D, Presecki P, Mimica N, Mustapic M, Pivac N, Babic A, Nedic G and Folnegovic-Smalc V: Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 33: 1226-1231, 2009.
43. Riederer P and Jellinger K: Morphological and biochemical changes in the aging brain: pathophysiological and possible therapeutic consequences. Exp Brain Res (Suppl 5): 158-166, 1982. (Pubitemid 12046586)
44. Battistin L, Rigo A, Bracco F, Dam M and Pizzolato G: Metabolic aspects of aging brain and related disorders. Gerontology 33: 253-258, 1987. (Pubitemid 17124829)
45. Mimica N, Mück-Seler D, Pivac N, Mustapić M, Dezeljin M, Stipcević T, Presecki P, Radonić E and Folnegović-Smalc V: Platelet serotonin and monoamine oxidase in Alzheimer's disease with psychotic features. Coll Antropol 32 (Suppl 1): 119-122, 2008.
46. Götz ME, Fischer P, Gsell W, Riederer P, Streifler M, Simanyi M, Müller F and Danielczyk W: Platelet monoamine oxidase B activity in dementia. A 4-year follow-up. Dement Geriatr Cogn Disord 9: 74-77, 1998.
47. Parnetti L, Reboldi GP, Santucci C, Santucci A, Gaiti A, Brunetti M, Cecchetti R and Senin U: Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. Aging (Milano) 6: 201-207, 1994.
48. Bonuccelli U, Piccini P, Marazziti D, Cassano GB and Muratorio A: Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease. J Neural Transm Park Dis Dement Sect 2: 139-147, 1990. (Pubitemid 20271086)
49. Kennedy BP, Ziegler MG, Alford M, Hansen LA, Thal LJ and Masliah E: Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. J Neural Transm 110: 789-801, 2003. (Pubitemid 36783232)
50. Delumeau JC, Bentué-Ferrer D, Gandon JM, Amrein R, Belliard S and Allain H: Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases. J Neural Transm Suppl 41: 259-266, 1994. (Pubitemid 24215700)
51. Grailhe R, Cardona A, Even N, Seif I, Changeux JP and Cloëz-Tayarani I: Regional changes in the cholinergic system in mice lacking monoamine oxidase A. Brain Res Bull 78: 283-289, 2009.
52. Riederer P, Danielczyk W and Grünblatt E: Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 25: 271-277, 2004.
53. Thomas T: Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 21: 343-348, 2000.
54. Soto J, Ulibarri I, Jauregui JV, Ballesteros J and Meana JJ: Dissociation between I2-imidazoline receptors and MAO-B activity in platelets of patients with Alzheimer's type dementia. J Psychiatr Res 33: 251-257, 1999. (Pubitemid 29178668)
55. Finali G, Piccirilli M, Oliani C and Piccinin GL: L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clin Neuropharmacol 14: 523-536, 1991.
56. Weinreb O, Mandel S, Bar-Am O and Amit T: Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J Neural Transm 118: 479-492, 2011.
57. Guay DR: Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother 4: 330-346, 2006.
58. Grünblatt E, Schlösser R, Fischer P, Fischer MO, Li J, Koutsilieri E, Wichart I, Sterba N, Rujescu D, Möller HJ, Adamcyk W, Dittrich B, Müller F, Oberegger K, Gatterer G, Jellinger KJ, Mostafaie N, Jungwirth S, Huber K, Tragl KH, Danielczyk W and Riederer P: Oxidative stress related markers in the 'VITA' and the centenarian projects. Neurobiol Aging 26: 429-438, 2005.
59. Wu RM, Mohanakumar KP, Murphy DL and Chiueh CC: Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline). Ann NY Acad Sci 738: 214-221, 1994.
60. Youdim MB, Amit T, Bar-Am O, Weinreb O and Yogev-Falach M: Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotox Res 10: 181-192, 2006.
61. Bar-Am O, Amit T, Weinreb O, Youdim MB and Mandel S: Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis 21: 361-371, 2010.
62. Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T and Youdim MB: Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics 6: 163-174, 2009.
63. Weinstock M and Groner E: Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity. Chem Biol Interact 175: 216-221, 2008.
64. Youdim MB, Fridkin M and Zheng H: Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 126: 317-326, 2005. (Pubitemid 40038353)
65. Adolfsson R, Gottfries CG, Oreland L, Wiberg A and Winblad B: Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27: 1029-1034, 1980. (Pubitemid 11252511)
66. Bongioanni P, Gemignani F, Boccardi B, Borgna M and Rossi B: Platelet monoamine oxidase molecular activity in demented patients. Ital J Neurol Sci 18: 151-156, 1997. (Pubitemid 127756895)
67. Ahlskog JE, Uitti RJ, Tyce GM, O'Brien JF, Petersen RC and Kokmen E: Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases. J Neurol Sci 136: 162-168, 1996. (Pubitemid 26101279)
68. Konings CH, Scheltens P, Kuiper MA and Wolters EC: No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease. Clin Chim Acta 240: 99-102, 1995.
69. Winblad B, Gottfries CG, Oreland L and Wiberg A: Monoamine oxidase in platelets and brains of non-psychiatric and non-neurological geriatric patients. Med Biol 57: 129-132, 1979. (Pubitemid 9187413)
70. Mann JJ, Stanley M, Neophytides A, de Leon MJ, Ferris SH and Gershon S: Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit. Neurobiol Aging 2: 57-60, 1981. (Pubitemid 11082134)
71. da Silva VB, de Andrade P, Kawano DF, Morais PA, de Almeida JR, Carvalho I, Taft CA and da Silva CH: In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity. Future Med Chem 3: 947-960, 2011.
72. Schneider LS, Severson JA, Chui HC, Pollock VE, Sloane RB and Fredrickson ER: Platelet tritiated imipramine binding and MAO activity in Alzheimer's disease patients with agitation and delusions. Psychiatry Res 25: 311-322, 1988.
73. Rodríguez MJ, Saura J, Billett EE, Finch CC and Mahy N: Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system. Cell Tissue Res 304: 215-220, 2001.
74. Sivasubramaniam SD, Finch CC, Rodriguez MJ, Mahy N and Billett EE: A comparative study of the expression of monoamine oxidase-A and -B mRNA and protein in non-CNS human tissues. Cell Tissue Res 313: 291-300, 2003. (Pubitemid 37260436)
75. Palmer AM and DeKosky ST: Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect 91: 135-159, 1993. (Pubitemid 23131301)
76. Reinikainen KJ, Paljärvi L, Halonen T, Malminen O, Kosma VM, Laakso M and Riekkinen PJ: Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging 9: 245-252, 1988.
77. Emilsson L, Saetre P, Balciuniene J, Castensson A, Cairns N and Jazin EE: Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients. Neurosci Lett 326: 56-60, 2002. (Pubitemid 34607593)
78. Burke WJ, Li SW, Schmitt CA, Xia P, Chung HD and Gillespie KN: Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death. Brain Res 816: 633-637, 1999. (Pubitemid 29225414)
79. Chan-Palay V, Höchli M, Savaskan E and Hungerecker G: Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease. Dementia 4: 1-15, 1993. (Pubitemid 23071252)
80. Barnett JH, Xu K, Heron J, Goldman D and Jones PB: Cognitive effects of genetic variation in monoamine neurotransmitter systems: a population-based study of COMT, MAOA, and 5HTTLPR. Am J Med Genet B Neuropsychiatr Genet 156: 158-167, 2011.
81. Klinteberg B, Levander SE, Oreland L, Asberg M and Schalling D: Neuropsychological correlates of platelet monoamine oxidase (MAO) activity in female and male subjects. Biol Psychol 24: 237-252, 1987. (Pubitemid 17151240)
82. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B and Klein DF: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 55: 1133-1141, 1998. (Pubitemid 28558287)
83. Goldstein DM and Goldberg RL: Monoamine oxidase inhibitor-induced speech blockage. J Clin Psychiatry 47: 604, 1986. (Pubitemid 17230035)
84. Delcker A and Gaertner HJ: Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor - an open study. Eur Neuropsychopharmacol 1: 177-180, 1991.
85. Danilova RA, Moskvityna TA, Obukhova MF, Belopolskaya MV and Ashmarin IP: Pargyline conjugate-induced long-term activation of monoamine oxidase as an immunological model for depression. Neurochem Res 24: 1147-1151, 1999. (Pubitemid 29413604)
86. Giacobini G, Marchisio PC, Giacobini E and Koslow SH: Developmental changes of cholinesterases and monoamine oxidase in chick embryo spinal and sympathetic ganglia. J Neurochem 17: 1177-1185, 1970.
87. Van der Schyf CJ, Gal S, Geldenhuys WJ and Youdim MB: Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs 15: 873-886, 2006. (Pubitemid 44177841)
88. Ikemoto K, Kitahama K, Maeda T, Jouvet M and Nagatsu I: Cholinergic neurons with monoamine oxidase type B (MAOB)-activity in the laterodorsal tegmental nucleus of the mouse. Neurosci Lett 271: 53-56, 1999. (Pubitemid 29369193)
89. Nakamura S, Akiguchi I and Kimura J: A subpopulation of mouse striatal cholinergic neurons show monoamine oxidase activity. Neurosci Lett 161: 141-144, 1993. (Pubitemid 23314853)
90. Panagiotidis G, Stenström A and Lundquist I: Effects of adrenergic and cholinergic stimulation on islet monoamine oxidase activity and insulin secretion in the mouse. Eur J Pharmacol 233: 285-290, 1993. (Pubitemid 23090069)
91. Pintar JE, Breakefield XO and Patterson PH: Differences in monoamine oxidase activity between cultured noradrenergic and cholinergic sympathetic neurons. Dev Biol 120: 305-308, 1987. (Pubitemid 17027120)
92. Garrick NA and Murphy DL: Monoamine oxidase type A: differences in selectivity towards l-norepinephrine compared to serotonin. Biochem Pharmacol 31: 4061-4066, 1982. (Pubitemid 13212417)
93. Spector S: Monoamine oxidase in control of brain serotonin and norepinephrine content. Ann NY Acad Sci 107: 856-864, 1963.
94. Kumagae Y, Matsui Y and Iwata N: Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol 55: 121-128, 1991.
95. Baron M, Perumal AS, Levitt M and Cannova G: Platelet monoamine oxidase in schizophrenia with beta-phenylethylamine and benzylamine as substrates. Biol Psychiatry 17: 479-483, 1982. (Pubitemid 12102521)
96. Lewinsohn R, Glover V and Sandler M: Beta-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: A source of some anomalies? Biochem Pharmacol 29: 777-781, 1980. (Pubitemid 10174236)
97. Moret C and Briley M: The importance of norepinephrine in depression. Neuropsychiatr Dis Treat 7 (Suppl 1): 9-13, 2011.
98. Levitan MN, Chagas MH, Crippa JA, Manfro GG, Hetem LA, Andrada NC, Salum GA, Isolan L, Ferrari MC and Nardi AE; Brazilian Medical Association: Guidelines of the Brazilian Medical Association for the treatment of social anxiety disorder. Rev Bras Psiquiatr 33: 292-302, 2011 (In Portugese).
99. Schneier FR: Pharmacotherapy of social anxiety disorder. Expert Opin Pharmacother 12: 615-625, 2011.
100. Engelborghs S and De Deyn PP: The neurochemistry of Alzheimer's disease. Acta Neurol Belg 97: 67-84, 1997. (Pubitemid 27293714)
101. Ishrat T, Parveen K, Khan MM, Khuwaja G, Khan MB, Yousuf S, Ahmad A, Shrivastav P and Islam F: Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res 1281: 117-127, 2009.
102. Schaeffer EL and Gattaz WF: Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl) 198: 1-27, 2008.
103. Tran MH, Yamada K and Nabeshima T: Amyloid beta-peptide induces cholinergic dysfunction and cognitive deficits: a minivreview. Peptides 23: 1271-1283, 2002. (Pubitemid 34786706)
104. Dhull DK, Jindal A, Dhull RK, Aggarwal S, Bhateja D and Padi SS: Neuroprotective effect of cyclooxygenase inhibitors in ICV-STZ induced sporadic Alzheimer's disease in rats. J Mol Neurosci 46: 223-235, 2012.
105. McNaull BB, Todd S, McGuinness B and Passmore AP: Inflammation and anti-inflammatory strategies for Alzheimer's disease - a mini-review. Gerontology 56: 3-14, 2010.
106. Cai ZY, Yan Y and Chen R: Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model. Neurosci Bull 26: 28-36, 2010.
107. Agostinho P, Cunha RA and Oliveira C: Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 16: 2766-2778, 2010.
108. Hardy J and Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002. (Pubitemid 34790756)
109. Song W, Zhou LJ, Zheng SX and Zhu XZ: Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes. Acta Pharmacol Sin 21: 557-563, 2000. (Pubitemid 30415637)
110. Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B and Nordberg A: Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 53: 37-46, 2012.
111. Hu MK, Liao YF, Chen JF, Wang BJ, Tung YT, Lin HC and Lee KP: New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins. Bioorg Med Chem 16: 1957-1965, 2008. (Pubitemid 351226580)
112. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M and Youdim MB: Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem 100: 490-502, 2007. (Pubitemid 46016026)
113. Ono K, Hasegawa K, Naiki H and Yamada M: Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro. Neurochem Int 48: 275-285, 2006. (Pubitemid 43177149)
114. Yogev-Falach M, Bar-Am O, Amit T, Weinreb O and Youdim MB: A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 20: 2177-2179, 2006.
115. Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S and Youdim MB: Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl: 457-465, 2006. (Pubitemid 44622238)
116. Zhiyou C, Yong Y, Shanquan S, Jun Z, Liangguo H, Ling Y and Jieying L: Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease. Neurochem Res 34: 1226-1235, 2009.
117. Liu H, Li Z, Qiu D, Gu Q, Lei Q and Mao L: The inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett 485: 83-88, 2010.
118. Yogev-Falach M, Amit T, Bar-Am O, Weinstock M and Youdim MB: Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 16: 1674-1676, 2002.
119. Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M and Amit T: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79: 172-179, 2005. (Pubitemid 40116432)
120. Youdim MB, Amit T, Bar-Am O, Weinstock M and Yogev-Falach M: Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. Ann NY Acad Sci 993: 378-393, 2003.
121. Kupershmidt L, Amit T, Bar-Am O, Youdim MB and Weinreb O: The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid Redox Signal 17: 860-877, 2012.
122. Yang HQ, Sun ZK, Ba MW, Xu J and Xing Y: Involvement of protein trafficking in deprenyl-induced alpha-secretase activity regulation in PC12 cells. Eur J Pharmacol 610: 37-41, 2009.
123. Tsunekawa H, Noda Y, Mouri A, Yoneda F and Nabeshima T: Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav Brain Res 190: 224-232, 2008.
124. Calderón-Garcidueñas L, Kavanaugh M, Block M, D'Angiulli A, Delgado-Chávez R, Torres-Jardón R, González-Maciel A, Reynoso-Robles R, Osnaya N, Villarreal-Calderon R, Guo R, Hua Z, Zhu H, Perry G and Diaz P: Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults. J Alzheimers Dis 28: 93-107, 2012.
125. Stozicka Z, Zilka N, Novak P, Kovacech B, Bugos O and Novak M: Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease. J Neuroinflammation 7: 64, 2010.
126. McGeer EG and McGeer PL: Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 19: 355-361, 2010.
127. Hensley K: Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis 21: 1-14, 2010.
128. Streit WJ: Microglial activation and neuroinflammation in Alzheimer's disease: a critical examination of recent history. Front Aging Neurosci 2: 22, 2010.
129. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Löffler J and Richards JG: Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62: 15-30, 1994. (Pubitemid 24287342)
130. Menazza S, Blaauw B, Tiepolo T, Toniolo L, Braghetta P, Spolaore B, Reggiani C, Di Lisa F, Bonaldo P and Canton M: Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. Hum Mol Genet 19: 4207-4215, 2010.
131. Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB and Mandel SA: From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. J Alzheimers Dis 30: 1-16, 2012.
132. Dimpfel W and Hoffmann JA: Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol 11: 2, 2011.
133. Youdim MB, Maruyama W and Naoi M: Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 41: 369-391, 2005. (Pubitemid 41078802)
134. Weinreb O, Amit T, Bar-Am O and Youdim MB: Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets 13: 483-494, 2012.
135. Weinreb O, Amit T, Bar-Am O and Youdim MB: A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int Rev Neurobiol 100: 191-215, 2011.
136. Alafuzoff I, Helisalmi S, Heinonen EH, Reinikainen K, Hallikainen M, Soininen H and Koivisto K: Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. Eur J Clin Pharmacol 55: 815-819, 2000. (Pubitemid 30201763)
137. Birks J and Flicker L: Selegiline for Alzheimer's disease. Cochrane Database Syst Rev: CD000442, 2003.
138. Wilcock GK, Birks J, Whitehead A and Evans SJ: The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatry 17: 175-183, 2002. (Pubitemid 34130310)
139. Birks J and Flicker L: Selegiline for Alzheimer's disease. Cochrane Database Syst Rev: CD000442, 2000.
140. Filip V and Kolibás E: Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci 24: 234-243, 1999.
141. Lawlor BA, Aisen PS, Green C, Fine E and Schmeïdler J: Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Int J Geriatr Psychiatry 12: 319-322, 1997.
142. Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J and Thal LJ: Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 10: 132-140, 1996. (Pubitemid 26306099)
143. Schneider LS, Olin JT and Pawluczyk S: A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry 150: 321-323, 1993. (Pubitemid 23046522)
144. Youdim MB: The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 3: 541-550, 2006.
145. Zheng H, Fridkin M and Youdim MB: Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease. Neurochem Res 35: 2117-2123, 2010.
146. Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB and Fridkin M: Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 13: 773-783, 2005. (Pubitemid 40093620)
147. Gökhan-Kelekçi N, Yabanoǧlu S, Küpeli E, Salgin U, Ozgen O, Uçar G, Yešilada E, Kendi E, Yešilada A and Bilgin AA: A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg Med Chem 15: 5775-5786, 2007.
148. Yamada M and Yasuhara H: Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 25: 215-221, 2004. (Pubitemid 38044183)
149. Yu PH: Pharmacological and clinical implications of MAO-B inhibitors. Gen Pharmacol 25: 1527-1539, 1994.